Effect of vasopressin and V1 receptors blockade on hypotensive action of ANP in normotensive [WKY] and spontaneously hypertensive rats

• Autorzy: Lapinski M , Stepniakowski K. , Januszewicz A. , Noszczyk B. , Szczepanska-Sadowska E.
• Języki publikacji: EN

Abstrakty

EN

The aim of the study was to find out whether vasopressin (AVP) modifies hypotensive and heart rate accelerating effects of atrial natriuretic peptide (ANP) in normotensive (WKY) and spontaneously hypertensive (SHR) conscious rats. The effect of i. v. administration of 1; 2 and 4 µg of ANP on blood pressure (MP) and heart rate (HR) was compared during i. v. infusion of 0.9% NaCl (NaCl), NaCl + AVP (1.2 ng kg⁻¹ min⁻¹) and NaCl + dEt₂ AVP (V₁ receptors antagonist, 0.5 µg kg⁻¹ min⁻¹). AVP increased MP in SHR and WKY and decreased HR in SHR. V₁ antagonist decreased MP and increased HR only in SHR. In SHR ANP decreased MP and increased HR during NaCl, AVP and V₁ antagonist infusion. In WKY these effects were observed only during AVP administration. In each experimental situation hypotension and tachycardia induced by ANP were greater in SHR than in WKY. In both strains ANP induced changes in MP and HR were enhanced during AVP in comparison to NaCl infusion. V₁ antagonist did not modify effects of ANP in WKY and SHR. The results indicate that ANP abolishes hypertensive response induced by blood AVP elevation and that the basal levels of endogenous vasopressin acting through V₁ receptors does not interfere with hypotensive action of ANP neither in WKY nor in SHR.

Słowa kluczowe

EN

spontaneous hypertension; vasopressin; normotensive rat; hypertension; atrial natriuretic peptide; rat; receptor antagonist; blood pressure

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 1992
• Tom: 43
• Numer: 1
• Opis fizyczny: p.65-78,fig.

Twórcy

autor

Lapinski M

• Medical Academy of Warsaw, ul.Banacha 1A, 02-097 Warsaw, Poland

autor

Stepniakowski K.

autor

Januszewicz A.

autor

Noszczyk B.

autor

Szczepanska-Sadowska E.

Bibliografia

• 1. Goetz K. Physiology and pathophysiology of atrial peptides. Am J Physiol 1988; 254: E1-E8.
• 2. Laragh J. Atrial natriuretic hormone, the renin-aldosteron axis and blood pressure electrolyte homeostatis. N Engl J Med 1985; 313: 1330-1340.
• 3. Kleinert H, Maack T, Atlas S, Januszewicz A, Sealey J. Atrial natriuretic factor inhibits angiotensin-, norepinefrine-, and potassium-induced vascular contractility. Hypertension 1984; 6 (Suppl I): I 143-147.
• 4. Łapiński M, Stepniakowski K, Januszewicz A, Noszczyk В, Szczepańska-Sadowska E. Atrial natriuretic factor enhances vasopressin-induced bradycardia in normotensive (WKY) but not in spontaneuosly hypertensive (SHR) rats. Europ J Clin Invest 1988; 18: 568-574.
• 5. Proctor KG, Bealer SL. Selective antagonism of hormone-induced vasoconstriction by synthetic atrial natriuretic factor in the rat microcirculation. Circ Res 1987; 61: 42-49.
• 6. Annand-Srivastava M, Frankis D, Cantin M, Genest J. Atrial natriuretic factor inhibits adenylate cyclase activity. Biochem Biophys Res Commun 1984; 121: 855-862.
• 7. Meyer-Lehnert H, Tsai P, Schrier R. Atrial natriuretic factor (ANF) inhibits arginine vasopressin stimulated Ca⁺ fluxes and cell contraction in vascular smooth muscle cells. Klin Wochenschr 1987; 65 (Suppl 8): 115-121.
• 8. Nambi P, Whitman M, Gessner G, Nambi A, Crooke S. Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci USA 1986; 83: 8492-8495.
• 9. Garcia R, Thibauit G, Gutkowska J. et al. Chronic infusion of low doses of atrial natriuretic factor (ANF Arg 101-Tyr 126) reduces blood pressure in conscious SHR without apparent changes in sodium excretion. Proc Soc Exp Med 1985; 179: 396-401.
• 10. Gellai M, De Wolf R, Kinter L, Beeuwkes I. The effect of atrial natriuretic factor on blood pressure, heart rate and renal functions in counscious, spontaneuosly hypertensive rats. Circ Res 1986; 59: 56-62.
• 11. Marsh K, Seymour A, Haley A. et al. Renal and blood pressure responses to synthetic atrial natriuretic factor in spontaneously hypertensive rats. Hypertension 1985; 7: 386-401.
• 12. Mohring J, Kintz J, Shoun J. Studies on the role of vasopressin in blood pressure control of spontaneously hypertensive rats with established hypertension (SHR, stroke-prone strain). J Cardiovasc Pharmacol 1979; 1: 593-608.
• 13. Manning M, Lammek B, Kruszyński M, Seto J, Sawyer WH. Design of potent and selective antagonists of vasopressor responses to arginine vasopressin. J Med Chem 1982; 25: 408-414.
• 14. Winer B. Statistical Principles in Experimental Design. New York, McGraw-Hill, 1970; pp 46-139 and 299-378.
• 15. Ginsburg M. Production, release, transportation and elimination of the neurohypophyseal hormones. In: Neurohypophysial hormones and similar peptides. Berde B., ed. Springer Verlag, Berlin, Heidelberg, New York, 1968; pp. 286-371.
• 16. Crofton J, Share L, Shade R, Allen C, Tarnowski D. Vasopressin in the rat with spontaneous hypertension. Am J Physiol 1978; 135: H361.
• 17. Mohring J, Kintz J, Schoun J. Role of vasopressin in blood pressure control of spontaneously hypertensive rats. Clin Sci Mol Med 1978; 5: 247s-250s.
• 18. Share L, Crofton J. The role of vasopressin in hypertension. Fed Proc 1984; 43; 103-106.